Switch theme
Sign up to access all valuation multiples
Vivos Inc is a radiation oncology medical device company. It is engaged in the development of RadioGel which is a brachytherapy device comprising highly insoluble particles delivered by needle injection using a water-polymer composite for high-dose treatment of non-resectable solid tumors. IsoPet is another product of the company used for the treatment of solid tumors in animals. The company derives revenue through sales of its products.
1994
1
Last FY Revenue $28K
Last FY EBITDA -$2.6M
$49.2M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Vivos achieved revenue of $28K and an EBITDA of -$2.6M.
Vivos expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Vivos valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $28K | XXX | XXX | XXX |
| Gross Profit | XXX | -$3K | XXX | XXX | XXX |
| Gross Margin | XXX | -11% | XXX | XXX | XXX |
| EBITDA | XXX | -$2.6M | XXX | XXX | XXX |
| EBITDA Margin | XXX | -9303% | XXX | XXX | XXX |
| EBIT | XXX | -$2.6M | XXX | XXX | XXX |
| EBIT Margin | XXX | -9303% | XXX | XXX | XXX |
| Net Profit | XXX | -$2.9M | XXX | XXX | XXX |
| Net Margin | XXX | -10396% | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 2, 2025, Vivos's stock price is $0.
Vivos has current market cap of $52.5M, and EV of $49.2M.
See Vivos trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $49.2M | $52.5M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 2, 2025, Vivos has market cap of $52.5M and EV of $49.2M.
Vivos's trades at 1758.1x EV/Revenue multiple, and -18.9x EV/EBITDA.
Equity research analysts estimate Vivos's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Vivos's P/E ratio is not available.
See valuation multiples for Vivos and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $52.5M | XXX | $52.5M | XXX | XXX | XXX |
| EV (current) | $49.2M | XXX | $49.2M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 1758.1x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -18.9x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -18.9x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -18.0x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -29.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialVivos's revenue per employee in the last FY averaged $28K, while opex per employee averaged $2.6M for the same period.
Vivos's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Vivos's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Vivos and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -9303% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $28K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $2.6M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 1160% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 9292% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Vivos acquired XXX companies to date.
Last acquisition by Vivos was XXXXXXXX, XXXXX XXXXX XXXXXX . Vivos acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Vivos founded? | Vivos was founded in 1994. |
| Where is Vivos headquartered? | Vivos is headquartered in United States of America. |
| How many employees does Vivos have? | As of today, Vivos has 1 employees. |
| Is Vivos publicy listed? | Yes, Vivos is a public company listed on PINX. |
| What is the stock symbol of Vivos? | Vivos trades under RDGL ticker. |
| Who are competitors of Vivos? | Similar companies to Vivos include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Vivos? | Vivos's current market cap is $52.5M |
| Is Vivos profitable? | Yes, Vivos is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
